Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 5, 2009, Pages 609-618

  Hayashi, Kengo ^a   Ohno Matsui, Kyoko ^a   Shimada, Noriaki ^a   Moriyama, Muka ^a   Hara, Wakako ^a   Yoshida, Takeshi ^a   Tokoro, Takashi ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bevacizumab; CNV; Pathologic myopia; PDT

Indexed keywords

BEVACIZUMAB; GATIFLOXACIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; MYOPIC SUBRETINAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; SUBRETINAL NEOVASCULARIZATION; THERAPY RESISTANCE; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 64449085512     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-1021-2     Document Type: Article

References (18)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241-1244
2. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization: A 10-year follow-up. Ophthalmology 110:1297-1305. doi: 10.1016/ S0161-6420(03)00461-5
3. Verteporfin in Photodynamic Therapy (VIP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP Report No. 1. Ophthalmology 108:841-852. doi: 10.1016/ S0161-6420(01)00544-9
4. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: two-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 110:667-673. doi: 10.1016/S0161-6420(02)01998-X
5. Lam DSC, Chan WM, Liu DTL, Fan DSP, Lai WW, Chang KKL (2004) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in Chinese eyes: A prospective series of 1 and 2 year follow-up. Br J Ophthalmol 88:1315-1319. doi: 10.1136/bjo.2004.041624
6. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hara W, Yoshida T, Tokoro T, Mochizuki M (2008) Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: Comparison with nontreated controls. Am J Ophthalmol 145:518-526. doi: 10.1016/j.ajo.2007.10.032
7. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Ohshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathologic myopia. Br J Ophthalmol 91:161-165. doi: 10.1136/bjo.2006.099887
8. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 91:157-160. doi: 10.1136/bjo.2006.096776
9. Chan WM, Lai TYY, Liu DTL, Lam DSC (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization. Six-months results of a prospective study. Ophthalmology 114:2190-2196. doi: 10.1016/ j.ophtha.2007.03.043
10. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960-963. doi: 10.1097/01.iae.0000240121.28034.c3
11. Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093-1094. doi: 10.1097/01.iae.0000254896.78766.74
12. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guera J, Amaya-Espinosa A, Solis-Vivanco A, reyna-Castelan E, Abraham-Marin M, Martinez-Castellanos MA, Aiello LP (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27:707-712
13. Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17:620-626
14. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, Fernandez M (2007) Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short-term results. Eye Dec 7 [Epub ahead of print], doi: 10.1038/sj.eye.6703052
15. Arias L, Planas N, Prades S, Caminai JM, Rubio M, Pujol O, Roca G (2008) Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to pathologic myopia: 6-month results. Br J Ophthalmol 92:1035-1039. doi: 10.1136/bjo.2007.130260
16. Ikuno Y, Sayanagi K, Soga K, Sawa M tsujikawa M, Gomi F, Tano Y (2008) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. Am J Ophthalmol Sep 5 [Epub ahead of print]. doi: 10.1016/j.ajo.2008.07.017
17. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. doi: 10.1016/j/ajo.2008.07.022
18. Tatar O, Adam A, Shinoda K et al (2006) Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 142:95-104. doi: 10.1016/j.ajo.2006.01.085